{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:00:57Z","timestamp":1784635257861,"version":"3.55.0"},"reference-count":24,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["2567-1"],"award-info":[{"award-number":["2567-1"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Thailand Research Fund under the Royal Golden Jubilee Ph.D. Program","award":["PHD\/0094\/2561"],"award-info":[{"award-number":["PHD\/0094\/2561"]}]},{"DOI":"10.13039\/501100017170","name":"Thailand Science Research and Innovation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100017170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jcim-2025-0057_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Psoriasis is a systematic skin disease. Treatment choice is limited due to unsatisfactory clinical efficacy. The study evaluated the safety of Deprungsith formulation following long-term administration (chronic toxicity test) and its potential modulatory effect on hepatic cytochrome P450 (CYP) enzymes in\u00a0rats.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0057_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Wistar rats were randomly grouped to receive Deprungsith (125, 500, and 1,000\u202fmg\/kg\/day) and the satellite (1,000\u202fmg\/kg bw) to observe reversibility, as well as distilled water (untreated control) for 9\u00a0months. The sentinel-1 group was for environmental risk assessment after 6\u00a0months, and the sentinel-2 group was for environmental risk assessment after 9\u00a0months). Clinical and behavioral signs, mortality, and histopathology were monitored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0057_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The chronic toxicity study of Deprungsith revealed no evidence of mortality or serious clinical signs at any dosage level. However, changes in WBC count, serum albumin, and sodium, were observed. Histopathological examination identified mild to moderate liver necrosis and renal interstitial inflammation. Low-dose (125\u202fmg\/kg bw) significantly induced CYP1A2 and CYP3A1, while high-dose (1,000\u202fmg\/kg bw) inhibited CYP1A2 and CYP3A1 activities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jcim-2025-0057_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Deprungsith formulation was well-tolerated with an MTD (maximum tolerated dose) and NOAEL (no-observed-adverse-effect level) of 1,000\u202fmg\/kg bw. Long-term use of Deprungsith formulation in psoriasis patients should be carefully monitored for therapeutic outcomes (side effects from accumulated levels or unsatisfactory efficacy from inadequate CYP1A2 and CYP3A1-mediated metabolism) and potential herb-drug interactions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jcim-2025-0057","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:10:32Z","timestamp":1754561432000},"page":"253-263","source":"Crossref","is-referenced-by-count":0,"title":["Chronic toxicity and modulatory effects of Deprungsith formulation in Wistar Albino rats"],"prefix":"10.1515","volume":"23","author":[{"given":"Yosita","family":"Kasemnitichok","sequence":"first","affiliation":[{"name":"Graduate Studies, Chulabhorn International College of Medicine, Thammasat University , Pathumthani , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monthaka","family":"Teerachaisakul","sequence":"additional","affiliation":[{"name":"Department of Thai Traditional and Alternative Medicine , Ministry of Public Health , Nonthaburi , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullayakorn","family":"Plengsuriyakarn","sequence":"additional","affiliation":[{"name":"Graduate Studies, Chulabhorn International College of Medicine, Thammasat University , Pathumthani , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kesara","family":"Na-Bangchang","sequence":"additional","affiliation":[{"name":"Graduate Studies, Chulabhorn International College of Medicine, Thammasat University , Pathumthani , Thailand"},{"name":"Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University , Pathumthani , Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"key":"2026072111003820017_j_jcim-2025-0057_ref_001","doi-asserted-by":"crossref","unstructured":"Chaiyamahapurk, WP. Prevalence and characteristics of psoriasis patients in a primary care area in Thailand. J\u00a0Med Assoc 2021;104:610\u20134.","DOI":"10.35755\/jmedassocthai.2021.04.11913"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_002","doi-asserted-by":"crossref","unstructured":"Woo, YR, Park, CJ, Kang, H, Kim, JE. The risk of systemic diseases in those with psoriasis and psoriatic arthritis: from mechanisms to clinic. Int J Mol Sci 2020;21:7041. https:\/\/doi.org\/10.3390\/ijms21197041.","DOI":"10.3390\/ijms21197041"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_003","doi-asserted-by":"crossref","unstructured":"Swindell, WR, Johnston, A, Xing, X, Voorhees, JJ, Elder, JT, Gudjonsson, JE. Modulation of epidermal transcription circuits in psoriasis: new links between inflammation and hyperproliferation. PLoS One 2013;8:e79253. https:\/\/doi.org\/10.1371\/journal.pone.0079253.","DOI":"10.1371\/journal.pone.0079253"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_004","doi-asserted-by":"crossref","unstructured":"Salgado-Boquete, L, Carrascosa, JM, Llamas-Velasco, M, Ruiz-Villaverde, R, de la Cueva, P, Belinch\u00f3n, I. A new classification of the severity of psoriasis: what\u2019s moderate psoriasis? Life (Basel) 2021;11:627. https:\/\/doi.org\/10.3390\/life11070627.","DOI":"10.3390\/life11070627"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_005","unstructured":"Kim, WB, Jerome, D, Yeung, J. Diagnosis and management of psoriasis. Can Fam Physician 2017;63:278\u201385."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_006","doi-asserted-by":"crossref","unstructured":"Lee, HJ, Kim, M. Challenges and future trends in the treatment of psoriasis. Int J Mol Sci 2023;24:210\u201322. https:\/\/doi.org\/10.3390\/ijms241713313.","DOI":"10.3390\/ijms241713313"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_007","doi-asserted-by":"crossref","unstructured":"Rendon, A, Sch\u00e4kel, K. Psoriasis pathogenesis and treatment. Int J Mol Sci 2019;20:145\u201350.","DOI":"10.3390\/ijms20061475"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_008","unstructured":"Thawornwet, PPK. Foundation for restoration and promotion of traditional Thai medicine and school ayurvedic treatment situation of Faculty of Applied Thai Traditional Medicine Siriraj Hospital Medicine Mahidol University textbook traditional Thai medicine (Phaetsat Songkhro). Bangkok: Suphawanichkan Pim; 2012."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_009","doi-asserted-by":"crossref","unstructured":"Na-Bangchang, K, Teerachaisakul, M, Muhamad, P, Kasemnitichok, Y, Sangnarong, N, Boonprasert, K, et al.. Antiproliferative and anti-inflammatory activities of deprungsith formulation and its bioactive compounds against mild psoriasis and potential of metabolic herb-drug interactions. J\u00a0Evid Based Integr Med. 2023;28:2515690x231191101. https:\/\/doi.org\/10.1177\/2515690x231191101.","DOI":"10.1177\/2515690X231191101"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_010","unstructured":"Seewaboon sireeratawong. Final report: the second phase of the research project of efficacy and safety of Dephrangsith for psoriasis treatment.; 2019."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_011","unstructured":"World Health Organization. WHO guideline on good manufacturing practices (GMP) for herbal medicine. 20 Avenue Appia, 1211 Geneva 27, Switzerland; 2007."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_012","unstructured":"World Health Organization. WHO guidelines for assessing quality of herbal medicines with reference to contaminants and residues. 20 Avenue Appia, 1211 Geneva 27, Switzerland; 2007."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_013","unstructured":"World Health Organization (WHO). Guidelines for the regulation of herbal medicines in the South-East Asia Region. New Delhi: WHO Regional Office for South-East Asia; 2004."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_014","doi-asserted-by":"crossref","unstructured":"Muhamad, N, Plengsuriyakarn, T, Na-Bangchang, K. Atractylodes lancea for cholangiocarcinoma: modulatory effects on CYP1A2 and CYP3A1 and pharmacokinetics in rats and biodistribution in mice. PLoS One 2022;17:e0277614. https:\/\/doi.org\/10.1371\/journal.pone.0277614.","DOI":"10.1371\/journal.pone.0277614"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_015","doi-asserted-by":"crossref","unstructured":"Patel, S, Patel, S, Kotadiya, A, Patel, S, Shrimali, B, Joshi, N, et al.. Age-related changes in hematological and biochemical profiles of Wistar rats. Lab Anim Res 2024;40:7\u201314. https:\/\/doi.org\/10.1186\/s42826-024-00194-7.","DOI":"10.1186\/s42826-024-00194-7"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_016","unstructured":"Mary, LA, Giknis, PD, Charles, B, Clifford, D. Clinical laboratory parameters for the Crl:CD(SD) rats. USA, Canada: Charles River Laboratories; 2006 Technical report."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_017","doi-asserted-by":"crossref","unstructured":"OECD guidelines for the testing of chemicals: repeated dose 90-day oral toxicity study in rodents (test no. 408). USA, UK, France, Germany: OECD Publishing; 2018. https:\/\/doi.org\/10.1787\/9789264070707-en","DOI":"10.1787\/9789264070707-en"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_018","doi-asserted-by":"crossref","unstructured":"Lee, J, Beers, JL, Geffert, RM, Jackson, KD. A review of CYP-mediated drug interactions: mechanisms and in\u00a0vitro drug-drug interaction assessment. Biomolecules 2024;14:99. https:\/\/doi.org\/10.3390\/biom14010099.","DOI":"10.3390\/biom14010099"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_019","doi-asserted-by":"crossref","unstructured":"Martignoni, M, Groothuis, GMM, de Kanter, R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Exp Opin Drug Metab Toxicol 2006;2:875\u201394. https:\/\/doi.org\/10.1517\/17425255.2.6.875.","DOI":"10.1517\/17425255.2.6.875"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_020","doi-asserted-by":"crossref","unstructured":"Amundsen, R, \u00c5sberg, A, Ohm, IK, Christensen, H. Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in\u00a0vitro. Drug Metab Dispos 2012;40:655\u201361. https:\/\/doi.org\/10.1124\/dmd.111.043018.","DOI":"10.1124\/dmd.111.043018"},{"key":"2026072111003820017_j_jcim-2025-0057_ref_021","unstructured":"Spear, SJ, McLachlan, JM. Cytochrome P450 1A2 and its role in carcinogenesis. Toxicol Appl Pharmacol 2001;171:74\u201380."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_022","unstructured":"Sirisangtrakul, W, Jarukamjorn, K, Nemoto, N, Yenjai, C, Sripanidkulchai, B. Effect of ethyl-p-methoxy cinnamate from Kaempferia galanga on cytochrome P450 enzymes expression in mouse hepatocytes. Chiang Mai J Sci 2011;38:253\u201360."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_023","unstructured":"S\u00f8rensen, HT, Christensen, S, Kragh Andersen, P, Johnsen, SP, Thomsen, RW, S\u00f8rensen, M, et al.. Impact of gender on drug metabolism and response. Eur J Clin Pharmacol 2006;62:501\u20137."},{"key":"2026072111003820017_j_jcim-2025-0057_ref_024","doi-asserted-by":"crossref","unstructured":"Qiang, Ma, Lu, Anthony YH. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab Dispos 2007;35:1009\u201316. https:\/\/doi.org\/10.1124\/dmd.107.015826.","DOI":"10.1124\/dmd.107.015826"}],"container-title":["Journal of Complementary and Integrative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0057\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0057\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:00:55Z","timestamp":1784631655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jcim-2025-0057\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,8]]},"published-print":{"date-parts":[[2026,7,2]]}},"alternative-id":["10.1515\/jcim-2025-0057"],"URL":"https:\/\/doi.org\/10.1515\/jcim-2025-0057","relation":{},"ISSN":["2194-6329","1553-3840"],"issn-type":[{"value":"2194-6329","type":"print"},{"value":"1553-3840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]}}}